Health · Enterprise
IgGenix, Inc.
IgGenix is a clinical-stage biotechnology company in South San Francisco developing fully human, allergen-specific antibody therapeutics for severe food and environmental allergies. Its proprietary SEQ SIFTER single-cell RNA-sequencing platform isolates the rare IgE-producing B cells behind allergic reactions and re-engineers them into protective IgG antibodies designed to block the allergic cascade. The lead candidate, IGNX001, is in a Phase 1 trial for peanut allergy.